Pedro Barata, MD, MSc

Articles

Clinical Pearls for Treating Advanced Renal Cell Carcinoma

April 14th 2023

Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, close their discussion with clinical pearls for community oncologists treating patients with advanced RCC.

Advanced RCC Treatments Following Prior Immune Checkpoint Inhibitors

April 7th 2023

Drs Barata and Garmezy give detailed thoughts on treating patients with advanced RCC who have received prior immune checkpoint inhibitors.

TIVO-3 Trial: Tivozanib for Patients With Advanced RCC

April 7th 2023

A comprehensive overview of the TIVO-3 trial, which compared tivozanib with sorafenib in patients with advanced renal cell carcinoma.

Advanced RCC Treatment Options Post-Progression

March 31st 2023

Experts on renal cell carcinoma discuss post-progression treatment options for RCC.

Considerations in Advanced RCC Treatment Selection

March 31st 2023

Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, outline factors taken into consideration when selecting advanced RCC treatments.

Front Line Trials in Advanced RCC

March 24th 2023

Renal cell carcinoma experts discuss clinical trials, evaluating immunotherapies and tyrosine kinase inhibitors in the front line setting of advanced RCC.

Patient Profile: A 67-Year-Old Man With Metastatic Clear Cell RCC

March 24th 2023

Benjamin Garmezy, MD, presents the case of a 67-year-old man diagnosed with advanced renal cell carcinoma.

Renal Cell Carcinoma Histology and Risk Stratification

March 17th 2023

Experts on renal cell carcinoma describe the RCC histologies and tools used for risk stratification.

Overview of Renal Cell Carcinoma

March 17th 2023

Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, open the discussion with an overview of renal cell carcinoma.

Dr. Barata on the Evolving Treatment Landscape in Urothelial Cancer

September 26th 2022

Pedro C. Barata, MD, MSc, discusses the evolving treatment landscape of urothelial cancer.

Dr. Barata on the Role of Maintenance Avelumab in Advanced Urothelial Cancer

August 29th 2022

Pedro C. Barata, MD, MSc, discusses the role of maintenance avelumab in advanced urothelial cancer.

Practical Considerations in Selecting Therapy for Metastatic CRPC

August 23rd 2022

Closing out their discussion on prostate cancer, expert panelists highlight which factors best inform selection of therapy for patients with mCRPC.

What is the Role of 177Lu-PSMA-617 in Metastatic CRPC?

August 23rd 2022

Panelists share insight on 177Lu-PSMA-617 and consider where it might fit into the treatment paradigm for metastatic castration-resistant prostate cancer.

Metastatic CRPC: Practical Selection and Use of PARP Inhibitors

August 16th 2022

Expert perspectives on how PARP inhibition will fit into the real-world management of patients with metastatic castration-resistant prostate cancer.

An Overview of PARP Inhibition in Metastatic CRPC

August 16th 2022

Focusing on the advent of PARP inhibitors in metastatic castration-resistant prostate cancer, genitourinary cancer specialists provide an overview of clinical trials and agents in this setting.

PTEN Loss in mCRPC: Caution Surrounding mTOR, PI3K, and AKT Inhibition

August 9th 2022

Panelists share caution toward use of mTOR-, PI3K-, and AKT-targeted therapies in the setting of PTEN loss in metastatic CRPC.

Therapy Overview: Sequencing Agents in Patients With Metastatic CRPC

August 9th 2022

A comprehensive review of available agents in the setting of metastatic CRPC, with discussion of optimal sequencing in later lines of therapy.

Metastatic Castration-Resistant Prostate Cancer: Optimal Imaging Strategies

August 2nd 2022

Expert oncologists define appropriate imaging strategies, conventional and novel, in patients with metastatic castration-resistant prostate cancer.

Clinical Scenario 3: A 76-Year-Old With Metastatic CRPC

August 2nd 2022

Shared insight on a clinical scenario of metastatic castration-resistant prostate cancer managed with androgen-deprivation therapy and docetaxel.

Addressing Unmet Needs in Nonmetastatic CRPC

July 26th 2022

Before closing out their second module, panelists highlight remaining unmet needs in the setting of nonmetastatic castration-resistant prostate cancer.